PWM
IBRX icon

Parkworth Wealth Management’s ImmunityBio IBRX Stock Holding History

Parkworth Wealth Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$18 Hold
7
– – ﹤0.01% 1343
2025
Q1 		$21 Buy
7
+4
+133% +$12 ﹤0.01% 1202
2024
Q4 		$8 Buy
+3
New +$12 ﹤0.01% 1266

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return

Parkworth Wealth Management's IBRX Position: Q2 2025 in Review

Parkworth Wealth Management held its ImmunityBio (IBRX) position steady in Q2 2025 at 7 shares worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #1343.

Parkworth Wealth Management first reported a position in IBRX in Q4 2024 and has held it in 3 quarters since. The position peaked at $21 in Q1 2025. 241 funds tracked by Wall St. Rank hold IBRX as of Q2 2025.

  • Parkworth Wealth Management held 7 shares of ImmunityBio worth $18 as of Q2 2025.
  • Parkworth Wealth Management left its ImmunityBio share count unchanged in Q2 2025.
  • ImmunityBio made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #1343 holding.
  • Parkworth Wealth Management first reported a position in ImmunityBio in Q4 2024 and has held it in 3 quarters since.
  • Parkworth Wealth Management's ImmunityBio position peaked at $21 in Q1 2025.
  • 241 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.